ACCLAIM Trial: Setting a New Standard in Colorectal Cancer Research

SIO has completed enrollment for the ACCLAIM Trial—hitting the target of 330 tumors eight months early. This global, prospective study is the first in interventional oncology to use a reproducible technical endpoint, helping set a higher standard for evidence-based care.

Principal Investigator:
Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE
Memorial Sloan Kettering Cancer Center

Learn More

TRIBUTE: A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases

The TRIBUTE trial, a multi-million-dollar project, is the first prospective, multi-center study to evaluate real-world outcomes—such as pain, patient-reported outcomes, skeletal-related events, and healthcare utilization—in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions.

Developed in collaboration with radiation oncology, TRIBUTE represents a critical multidisciplinary partnership and is the second multi-industry supported clinical study executed by SIO, following the ACCLAIM Trial.

For study inquiries, please email TRIBUTE@sio-central.org.

Clinical Trial Leadership

Jack Jennings, MD, PhD, FSIR

Professor, Radiology and Orthopedic Surgery
Washington University School of Medicine, St. Louis

Clifford Robinson, MD

Professor, Radiation Oncology and Medicine
Washington University School of Medicine, St. Louis

Sean Tutton, MD, FSIR, FCIRSE

Professor, Radiology and Orthopedics
University of California, San Diego

James Urbanic, MD

Professor, Clinical Radiation Medicine and Applied Sciences
University of California, San Diego